

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1-8. (Canceled)

9. (Currently Amended) A regime for determining whether or not a sample of skin or of a skin equivalent contains ~~an amount of~~ a papillary fibroblast population ~~so as to be considered a normal skin~~, comprising the steps of:

(a) labeling the skin or skin equivalent with at least one antibody specific for papillary fibroblasts, and wherein the at least one antibody specific for papillary fibroblasts includes an anti-PG4 monoclonal antibody; and

(b) evaluating the sample of skin or the sample of skin equivalent for any labeling, ~~to determine~~ determining whether the skin or skin equivalent is a normal skin, wherein the presence of labeling in the sample of skin or in the sample of skin equivalent indicates that the sample of skin or the sample of skin equivalent skin or skin equivalent is a normal skin ~~and wherein the at least one antibody comprises a PG4 monoclonal antibody~~.

10. (Previously Presented) The regime of claim 9, wherein the labeling is present at the upper dermis at the level of the epidermis.

11. (Currently Amended) A regime for determining the presence of papillary fibroblasts in a ~~given~~ sample, comprising:

(a) labeling said sample with at least one antibody specific for papillary fibroblasts, and wherein the at least one antibody comprises an anti-PG4 monoclonal antibody; and

(b) evaluating ~~any labeling~~ determining presence of bound antibody as a marker for the presence of said papillary fibroblasts, ~~wherein the at least one antibody comprises a PG4 monoclonal antibody~~.

12. (Previously Presented) The regime of Claim 11, wherein the sample is a skin or skin equivalent sample.

13. (Previously Presented) The regime of Claim 12, wherein the labeling is present at the upper dermis at the level of the epidermis in the skin or skin equivalent sample.